Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

NCT07570810 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tests whether combining the drug CS0159 with semaglutide helps reduce body weight in adults who have obesity, type 2 diabetes, and non-alcoholic fatty liver disease.

Status Not yet recruiting Approved but enrollment has not started.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 30 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2026-06 · est. completion 2026-12

What this study is testing ClinicalTrials.gov NCT07570810 ↗

Description as written by the study sponsor.

This is an exploratory study evaluating CS0159 in combination with Semaglutide in metabolic dysfunction-associated fatty liver disease (MAFLD) patients with obesity and type 2 diabetes (T2DM).

Treatments tested

CS0159 Drug

The intervention will include a 12-week treatment period. During the 12-week treatment period, subjects will receive 4mg CS0159 (oral, once daily).
CS0159 placebo Drug

The intervention will include a 12-week treatment period. During the 12-week treatment period, subjects will receive CS0159 placebo (oral, once daily).
Semaglutide Drug

The intervention will include a 12-week treatment period. During the 12-week treatment period, subjects will receive 0.5mg Semaglutide (subcutaneous injection, once weekly).

Main thing measured	Percentage change in body weight relative to baseline
Sponsor	Shanghai Jiao Tong University School of Medicine
Conditions studied	Type 2 Diabetes, Obesity, Non-alcoholic Fatty Liver Disease
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07570810 ↗